Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CSIRO based drug effective against bird flu

20.02.2004



Drugs based on CSIRO’s research into the influenza virus have been shown to be effective, in laboratory tests, against a sample of an H5N1 influenza virus currently infecting chickens in Asia.

CSIRO Health Sciences and Nutrition scientist, Dr Jenny McKimm-Breschkin, has tested the ability of the flu drug Relenza™ to inhibit the virus, known as H5N1 strain, which has killed millions of chickens in Asia and has been responsible for several human deaths this year.

The tests, used to monitor virus sensitivity to drugs, have shown that the drug Relenza™ is as effective, in laboratory experiments, against this bird flu as it is against other strains of flu that affect humans.



"There is a direct correlation between enzyme sensitivity as measured by these laboratory tests and the ability of the drug to prevent the virus from multiplying," said Dr McKimm-Breschkin.

In 1999, the world’s first drug effective against all strains of influenza was released onto the world market. Relenza™ was designed based on CSIRO’s discovery that there was a small section on the surface of the influenza virus that doesn’t change between strains of flu. Designing a drug to inhibit the action of this part of the virus meant it would be very difficult for the virus to mutate to avoid binding the drug. No drug resistance has been seen globally in any previously healthy patient treated with Relenza™.

Subsequently a second drug, Tamiflu™, was developed based on CSIRO research. Its manufacturers claim that pre-clinical trials provide reassurance that it could be effective against bird flu.

The Asian bird flu has not been shown to be passed from human to human. All those who have died from this disease have caught it directly from infected birds. The current strategy for preventing this virus from spreading further and endangering more humans has been to cull millions of chickens in Asian farms and markets.

"In the event that the disease does mutate into a form which can be passed from human to human it is important to know that we already have a treatment available," said Dr McKimm-Breschkin. "The fact that our experiments show that in the laboratory this Australian designed drug is effective against bird flu again shows just how important a discovery this was."

In order to establish that Relenza™ is effective in humans infected with bird flu, clinical data from humans will be needed.

The same techniques used in the development of Relenza™ are being employed by CSIRO to fight other diseases such as cancer, psoriasis and inflammatory diseases like rheumatoid arthritis.

It should be noted that CSIRO receives a royalty income from sales of Relenza™. The assay results reported here have been conducted independently of the manufacturers of Relenza™.

More information:

Mr Warrick Glynn, CSIRO Health Sciences and Nutrition,
PH: 61 3 9662 7344, Mobile: 0408 117 846
Email: Warrick.Glynn@csiro.au

Rosie Schmedding | CSIRO
Further information:
http://www.csiro.au/index.asp?type=mediaRelease&id=PrBirdFlu5

More articles from Agricultural and Forestry Science:

nachricht Plasma-zapping process could yield trans fat-free soybean oil product
02.12.2016 | Purdue University

nachricht New findings about the deformed wing virus, a major factor in honey bee colony mortality
11.11.2016 | Veterinärmedizinische Universität Wien

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>